Sign in Subscribe
Cancer research

Liquid Biopsy Market Set to Transform Oncology with Robust Growth

Strategic Insights

— 2 min read

The global liquid biopsy market is projected to undergo significant transformation in the coming years, driven by the increasing prevalence of cancer, adoption of minimally invasive diagnostic tests, and advances in biomarker discovery. The market is expected to grow from USD 11.41 Billion in 2024 to USD 30.65 Billion by 2035, at a CAGR of 9.41% during 2025-2035. Liquid biopsy technology offers a non-invasive alternative for early cancer screening, recurrence monitoring, and personalized therapy decisions, leveraging circulating tumor DNA (ctDNA), exosomes, and circulating tumor cells (CTCs).

Key Takeaways:

  • North America accounted for 46.2% of the global revenue share in 2024, driven by advanced healthcare infrastructure, widespread adoption of cutting-edge diagnostic technologies, and substantial investments in research and development.
  • Assay Kits led the market in 2024 with a 52.5% share, reflecting their vital role in enabling precise detection and analysis of cancer biomarkers from minimal blood samples.
  • Cell-free DNA (cfDNA) was the top biomarker segment in 2024, capturing 46.5% of the market, highlighting its importance in non-invasive cancer diagnostics.
  • Multi-Gene Parallel Analysis via Next-Generation Sequencing (NGS) dominated in 2024 with a 76.2% share, owing to its ability to simultaneously evaluate multiple genes with superior accuracy and efficiency.
  • Cancer Applications commanded 85.1% of the market in 2024, reaffirming their central role in oncology diagnostics and treatment monitoring.
  • Blood samples remained the preferred source in 2024, representing 68.1% of the market share, due to their ease of collection and clinical reliability.
  • Hospitals & Physician Laboratories led the end-user segment with a 43.1% share in 2024, supported by their established infrastructure, large patient base, and integration of advanced liquid biopsy assays.

Statistics:

  • Market size: USD 11.41 Billion (2024)
  • Projected market size by 2035: USD 30.65 Billion
  • Growth rate: 9.41% CAGR (2025-2035)
  • Top market share by region: North America (46.2%, 2024)
  • Top market share by product: Assay Kits (52.5%, 2024)
  • Top biomarker segment: Cell-free DNA (cfDNA) (46.5%, 2024)
  • Top analytical method: Multi-Gene Parallel Analysis via Next-Generation Sequencing (NGS) (76.2%, 2024)
  • Dominant application: Cancer Applications (85.1%, 2024)
  • Preferred source: Blood samples (68.1%, 2024)
  • Leading end-user segment: Hospitals & Physician Laboratories (43.1%, 2024)

Sources:

  • Vantage Market Research. (2024). Liquid Biopsy Market Size, Share & Trends Analysis Report by Product, Biomarker, Application, End User, and Region - Historic Data (2021-2023), Base Year (2024) & Forecast Period (2025-2035).
  • [No other sources are mentioned in the original text.]

Read more